First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)-Reference-Cited by-同舟云学术

First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)

Published:2014-04-08 Issue:7 Volume:210 Page:1052-1061
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Baden Lindsey R.,Walsh Stephen R.,Seaman Michael S.,Johnson Jennifer A.,Tucker Robert P.,Kleinjan Jane A.,Gothing Jon A.,Engelson Brian A.,Carey Brittany R.,Oza Avinash,Bajimaya Shringkhala,Peter Lauren,Bleckwehl Chelsea,Abbink Peter,Pau Maria G.,Weijtens Mo,Kunchai Meghan,Swann Edith M.,Wolff Mark,Dolin Raphael,Barouch Dan H.

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Reference38 articles.

1. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial;Lancet,2008

2. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection;J Infect Dis,2005

3. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis;Lancet,2008

4. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand;N Engl J Med,2009

5. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study;Lancet Infect Dis,2011

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of adenoviral vectors in gene therapy and vaccine approaches;Genetics and Molecular Biology;2022

2. Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees;Open Forum Infectious Diseases;2020-12-15

3. An evidence map of randomised controlled trials evaluating genetic therapies;BMJ Evidence-Based Medicine;2020-11-10

4. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity;Journal for ImmunoTherapy of Cancer;2020-08

5. Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: “Adenovirus Vaccine Within an Adenovirus Vector”;Virologica Sinica;2020-05-26